2,079 results for event

Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a846abcbc3c40b098f391993ad2ec05&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a8432fd7c9d4e4ea754cdba08e89897&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a82880041494ceb8e098a7b8f1592f6&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a849cd311914874bc7ae79b1252b864&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a8477dc58bb4a1a80c41aa3fe3c4eea&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a82b9fd933246b8b6bc55bcd6de31ee&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a8306c9f10c4ba8932bb2e77c765295&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a83a7ff336d493880e4737c8f0bf5cf&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84d969033a46c0a6b465d286c86ec6&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a82bc909db84e898951ffccd1630a34&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a83583773a44bf88339db4897759dd5&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84926d14df4e06a54d2d5ea997078e&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a82934f6c764b98a3093c932e420d64&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a834e726c8143b795bfaeb4e281241d&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84f14cd9964114b008dd30b22301c3&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a8441da9c834dc1933729fc7bb7c207&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84adde0e0647beb232457b4ba759fc&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a848488fd9c437bb8ecf364e28e4410&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a83213537cf4206b0ef87816480eade&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a82b76d0d2f495eb4a2f841ff43b274&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.
Apr 27, 2022 9:45 AM